Recruiting PHASE1 INTERVENTIONAL 4-arm NCT06692192

The RECAP2 Study: Midazolam and Psilocybin

Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

Sponsor: University of Wisconsin, Madison

Conditions Psilocybin

Interventions Midazolam Psilocybin Saline

Updated 10 times since 2024 Last updated: Dec 22, 2025 Started: Aug 7, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06692192, this PHASE1 trial focuses on Psilocybin and remains actively recruiting participants. Sponsored by University of Wisconsin, Madison, it has been updated 10 times since 2025, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE1
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1
Aug 2025 — Oct 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 5 earlier versions

Jul 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1
May 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE1
Mar 2025 — May 2025 [monthly]

Not Yet Recruiting PHASE1
Jan 2025 — Mar 2025 [monthly]

Not Yet Recruiting PHASE1
Dec 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Wisconsin, Madison
Vail Health Foundation

Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States